Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

DISEASE CHARACTERISTICS:

Diagnosis of 1 of the following:

Aplastic anemia not responsive to immunosuppressive therapy
Metastatic renal cell carcinoma

Hematologic malignancy, including any of the following:

Acute myeloid leukemia (AML)* not curable with chemotherapy and meeting any of the following criteria:

AML with high-risk cytogenetic abnormalities (e.g., -7, -7q, -5, -5q, complex, Philadelphia chromosome-positive [Ph+])
AML evolved from prior myelodysplasia
AML secondary to prior chemotherapy
Failed to achieve remission
In second or subsequent remission NOTE: *Marrow blasts < 10%- can be achieved by chemotherapy

Myelodysplasia* with any of the following high-risk features:

Adverse cytogenetics (-7, 7q, -5, -5q, complex)
Excess blasts
Prior conversion to AML
Severe cytopenias with absolute neutrophil count < 500/mm^3 or platelet count < 20,000/mm^3 NOTE: *Marrow blasts < 10%- can be achieved by chemotherapy

Acute lymphoblastic leukemia (ALL)* not curable with chemotherapy and meeting any of the following criteria:

High-risk cytogenetics (Ph+, 11q23 abnormalities, monosomy 7)
More than 1 induction course required to achieve remission
Failed to enter remission
In second or subsequent remission NOTE: *Marrow blasts < 10 %

Chronic lymphocytic leukemia (CLL) with high-risk features, including any of the following:

Refractory to initial or subsequent therapy
Progression after initial response to therapy
Prolymphocytic morphology

Follicular lymphoma with any of the following high-risk features:

Refractory to initial or subsequent therapy
Progression after response to initial therapy
Has ≥ 3 International Prognostic Index (IPI) risk factors

Multiple myeloma

Stage II-III disease confirmed at diagnosis or after initial progression

Other lymphoma that has failed to respond to primary therapy, progressed, or recurred after prior therapy, including any of the following:

Diffuse large cell lymphoma
Mantle cell lymphoma
Hodgkin's lymphoma

Myeloproliferative disease with evidence of disease acceleration, including any of the following:

Myelofibrosis
Polycythemia vera
Essential thrombocythemia
Chronic myeloid leukemia (CML) that failed to be controlled by imatinib mesylate
Disease must be stable or responding to therapy

No rapid progression of malignant disease

Expected time to disease progression > 12 weeks
Not eligible for autologous stem cell transplantation

Matched unrelated donor available

9/10 HLA matched, including HLA-A, -B, -C, -DR, and -DQ

PATIENT CHARACTERISTICS:

Creatinine < 2.0 mg/dL
Creatinine clearance > 40 mL/min

Bilirubin < 3 mg/dL

Elevated total bilirubin due to Gilbert's disease allowed if direct bilirubin is normal
AST < 4 times upper limit of normal
Hepatitis C or B allowed provided bilirubin and AST are normal
Cardiac ejection fraction > 30%
DLCO > 40% of predicted
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
No uncontrolled active infection requiring ongoing antibiotic treatment
No poor performance status
No poor organ function

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
Prior stem cell or bone marrow transplantation allowed